Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Change in Receivables (2021 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Change in Receivables for 5 consecutive years, with $1.0 million as the latest value for Q1 2025.

  • Quarterly Change in Receivables rose 280.18% to $1.0 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 million through Dec 2025, up 140.96% year-over-year, with the annual reading at $1.0 million for FY2025, 140.96% up from the prior year.
  • Change in Receivables for Q1 2025 was $1.0 million at Whitehawk Therapeutics, up from -$637000.0 in the prior quarter.
  • The five-year high for Change in Receivables was $3.7 million in Q1 2023, with the low at -$14.0 million in Q1 2021.
  • Average Change in Receivables over 5 years is -$483066.7, with a median of -$120000.0 recorded in 2021.
  • The sharpest move saw Change in Receivables plummeted 437.5% in 2022, then surged 930.81% in 2023.
  • Over 5 years, Change in Receivables stood at -$120000.0 in 2021, then crashed by 232.5% to -$399000.0 in 2022, then soared by 42.61% to -$229000.0 in 2023, then crashed by 178.17% to -$637000.0 in 2024, then skyrocketed by 256.99% to $1.0 million in 2025.
  • According to Business Quant data, Change in Receivables over the past three periods came in at $1.0 million, -$637000.0, and $620000.0 for Q1 2025, Q4 2024, and Q3 2024 respectively.